Funding for this research was provided by:
National Institute of Arthritis and Musculoskeletal and Skin Diseases (RO1AR78340)
National Institute of Neurological Disorders and Stroke (U24NS107210)
Article History
Accepted: 21 July 2022
First Online: 4 August 2022
Compliance with Ethical Standards
:
: Drs. Stevens and Milani declare that they have no financial interests. Dr. Mozaffar discloses an advisory role for and/or receiving research funds from Alexion, Amicus, Argenx, Arvinas, Audentes, AvroBio, Horizon Therapeutics, Immunovant, Maze Therapeutics, Momenta (now Janssen), Sanofi-Genzyme, Sarepta, Spark Therapeutics, UCB, and Modis/Zogenix. Dr. Mozaffar also serves on the data safety monitoring board for Acceleron, Avexis, and Sarepta.
: This article does not contain any studies with human or animal subjects performed by any of the authors.